Skip to content Skip to footer
Join our LinkedIn Group and be part of the conversation on AI in life sciences
Login
Close

Meghan Oates-Zalesky 

Meghan Oates‑Zalesky is Chief Marketing Officer at CapeStart and MadeAi, with over 20 years of experience in healthcare technology and life sciences. Previously CMO at Apollo Intelligence, she helped grow the company from a small startup into a global enterprise. A PharmaVOICE Woman of Influence (2021), Meg’s thought leadership has appeared in leading industry publications. She holds degrees from Harvard and the London School of Economics and is a published novelist and avid equestrian.

67 articles published Follow:
AI Life Sciences

2026 Prediction #1: No More Sandboxes: AI Enters the Core of Life Sciences

BlogMarch 3, 2026212Views0Likes0Comments
For the last several years, artificial intelligence in life sciences has largely lived in innovation labs and pilot programs—valuable but often disconnected from the workflows that actually drive regulatory approvals, market access, and clinical decision-making. In 2026, that changes. Our first prediction from MadeAi & CapeStart’s 2026 outlook, developed with insights from Angeline Dhas, Head…

Read More

Build – Operate – Transfer_ A narrative framework for Enterprise AI Adoption in Life Sciences

Build – Operate – Transfer: A narrative framework for Enterprise AI Adoption in Life Sciences

White PaperFebruary 19, 202671Views0Likes0Comments
In highly regulated life sciences environments, AI adoption is often delayed due to compliance, data security, and ownership concerns. MadeAi addresses these challenges by delivering compliant, auditable AI solutions through a structured Build–Operate–Transfer approach that ensures long-term ownership and control. The Build–Operate–Transfer (BOT) model supports phased AI adoption by collaboratively developing compliant solutions and validating…

Read More